Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection

Completed

Conditions studied: Hepatitis C Infection

In brief

The purpose of this observational study is to compare two approved treatment regimen(s) containing boceprevir and telaprevir, as part of standard of care for the treatment of hepatitis C.

Key facts

Study ID

NCT01771653

Run by

Southern Illinois University

People needed

37

Starts

2011-09-01

Expected to finish

2015-07-01

Last updated by the study team

2016-01-18

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age - 18-64 years
• HCV genotype 1
• HCV RNA >100,000
• Liver biopsy within 5 years before enrollment
• Absolute neutrophil count of at least 1200 per cubic millimeter
• Platelet count of at least 90,000 per cubic millimeter
• Hemoglobin level of at least 12 g per deciliter
• Signed informed consent and Health Insurance Portability and Accountability Act (HIPAA) forms

You may not qualify if…

• HCV genotypes other than genotype 1
• Immunocompromised conditions including HIV, transplant or immunosuppressive drugs
• Decompensated liver disease or hepatocellular carcinoma
• Any other types of active cancer
• Active autoimmune disorders
• Major psychiatric disorders
• Active drug or alcohol use
• Pregnancy or lactation
• Patients with allergy to any of the drugs used in this study
• Drugs that may interact with boceprevir or telaprevir as listed in the package insert

Where it is running

• Southern Illinois University School of Medicine — Springfield, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.